In addition, polymorphisms of ERCC1, ERCC2(XPD), XPA and XPC have been found to be associated with radiotherapy efficacy in a variety of tumors, including HNSCC, and may be important predictors of clinical outcomes in patients treated with radiotherapy (55–60). Here, ERCC2 is linked to head and neck squamous cell carcinoma.